By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...

Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in ...

Pfizer made one thing clear this week: It's officially back in the obesity race.

Pfizer reported weight-loss results for a monthly GLP-1 obesity injection that it acquired as part of the $10 billion Metsera ...

Pfizer signaled some promise in its long-running attempt to develop an anti-obesity drug on Tuesday, but analysts say limited results and missing safety information left Wall Street still uncertain ...

Pfizer shares fell 3.3% Tuesday on what some market watchers called underwhelming study results for an experimental weight-loss drug the drugmaker obtained after a contentious and costly bidding war ...

With data from a mid-stage trial showing weight loss of up to 12.3% at 28 weeks in patients treated with PF’3944, "Pfizer is moving full speed into obesity clinical development,” BMO Capital Markets ...

The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation ...

The drugmaker shared limited early results from a Metsera obesity treatment as investors weigh its $10 billion acquisition and declining Covid sales.

Pfizer reported strong mid-stage weight loss trial results for its monthly obesity drug and posted fourth-quarter earnings ...

A third dose of the Pfizer/BioNTech COVID-19 vaccine can "strongly" boost protection against the delta variant -- beyond the protection afforded by the standard two doses, suggests new data released ...